Hua Medicine (Shanghai) Ltd. (2552.HK) HKSE
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
Hua Medicine (Shanghai) Ltd.
Address
Hua Medicine, Building 2, Lane 36
Shanghai, SH 201203
China
Phone
862158869997
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
424
First IPO Date
September 14, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Li Chen | Founder, CEO, Member of Portfolio Advisory Board & Executive Director | 11.89M | 1963 |
| Yi Zhang | Senior Vice President of Pharma Development, Chief Medical Officer China and Executive Director | 5.43M | 1975 |
| Chien Cheng Lin | Executive Vice President, Chief Strategy Officer & Executive Director | 6.65M | 1971 |
| Nelly Au-Yeung | Company Secretary | 0 | N/A |
| Fuxing Tang | Chief Technology Officer, Vice President of Chemical Manufacturing Control Department and Head of R&D in USA | 0 | 1967 |
| Chengde Wang | Head of IR | 0 | 1948 |
| Yu Lu | Vice President of Sales & Marketing | 0 | 1975 |
| Ying Xie | Vice President of Quality Assurance Division & Chief Quality Officer | 0 | 1980 |
| Changhong Li | Chief Scientific Officer | 0 | 1970 |
Description
Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.
